Comparative Pharmacology
Head-to-head clinical analysis: POSLUMA versus PROSTASCINT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POSLUMA versus PROSTASCINT.
POSLUMA vs PROSTASCINT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PSMA-targeted radiotherapeutic agent; emits beta radiation causing DNA damage and cell death in PSMA-expressing cells.
PROSTASCINT is a murine monoclonal antibody fragment (capromab pendetide) conjugated to the chelating agent glycyl-tyrosyl-lysyl-diethylenetriaminepentaacetic acid (GYK-DTPA) and labeled with indium-111. It binds to the intracellular epitope of prostate-specific membrane antigen (PSMA) expressed on prostate epithelial cells and is used for imaging prostate cancer.
1.85 MBq (0.05 mCi)/kg intravenously as a single injection, followed by PET imaging approximately 60 minutes post-injection.
5 mCi (185 MBq) intravenously over 5 minutes, single dose.
None Documented
None Documented
Terminal elimination half-life: approximately 25–30 minutes for [68Ga]Ga-PSMA-11; rapid clearance from blood pool due to renal and hepatobiliary elimination.
Terminal elimination half-life: 2.6 ± 0.7 days (requires 2 weeks for complete clearance; used for radioimmunodetection within 5–7 days post-injection)
Renal: 0% (not significantly eliminated via kidneys); Biliary/Fecal: predominantly eliminated via hepatobiliary system with fecal excretion of intact complex and metabolites, though precise % not established for human.
Renal: ~90% (predominantly as intact tracer), Fecal: <5%
Category C
Category C
Radiopharmaceutical Diagnostic Agent
Radiopharmaceutical Diagnostic Agent